| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font
First page > Show document

Show document Help

Title:Matematično modeliranje vpliva nesteroidnih antirevmatikov na aspirinsko intoleranco astme
Authors:ID Dobovišek, Andrej (Author)
ID Brumen, Milan (Mentor) More about this mentor... New window
Files:.pdf DR_Dobovisek_Andrej_2012.pdf (5,74 MB)
MD5: E997287A9FBE458640CD87EB6D462E51
PID: 20.500.12556/dkum/362fea58-d54b-4c44-aede-f888e0a5d118
 
Language:Slovenian
Work type:Dissertation
Typology:2.08 - Doctoral Dissertation
Organization:FNM - Faculty of Natural Sciences and Mathematics
Abstract:Pri približno 10−20 % astmatičnih bolnikov se po zaužitju aspirina, ibuprofena ali katerega drugega nesteroidnega antirevmatika (NSAR) razvije bronhokonstrikcija, vnetje sluznic nosu, žrela in vnetje oči ter izpuščaji na koži. Ta pojav imenujemo aspirinska intoleranca. Raziskave kažejo, da so pri aspirinsko-intolerantnih astmatikih v primerjavi z aspirinsko-tolerantnimi astmatiki in neastmatiki bistveno spremenjene genske ekspresije encimov prostaglandin H sintaz 1 in 2 (PGHS1 in PGHS2) ter levkotrien C4 sintaze (LTC4S) pri presnovi arahidonske kisline (AA) v belih krvnih celicah. Ključnega pomena pri razvoju bronhokonstrikcije in drugih simptomov aspirinske intolerance sta produkta presnove AA: vnetni mediator levkotrien C4 (LTC4) in protivnetni prostaglandin E2 (PGE2). NSAR inhibirajo PGHS1 in PGHS2, kar zniža koncentracijo PGE2 in poviša koncentracijo LTC4 v celicah. V doktorskem delu izdelamo matematični model, ki omogoča študij vpliva NSAR na pojav aspirinske intolerance. Osredotočimo se na modeliranje ciklooksigenazne in lipoksigenazne poti presnove AA, pri čemer upoštevamo tudi inhibitorni učinek NSAR na encima PGHS1 in PGHS2. Časovni potek koncentracije NSAR v krvni plazmi po zaužitju zdravila pa opišemo s standardnim farmakokinetičnim modelom, v katerem upoštevamo fazo absorpcije zdravila v krvno plazmo in eliminacije iz krvne plazme. Razmerje med koncentracijama PGE2 in LTC4 uporabimo kot osrednji kriterij za napoved bronhokonstrikcije, pri čemer je tveganje za pojav bronhokonstrikcije večje, kadar je razmerje med koncentracijama PGE2 in LTC4 manjše od ena. Z modelom preučujemo pojav aspirinske intolerance na treh različnih ravneh; najprej na ravni ekspresij encimov PGHS1, PGHS2 in LTC4S, nato na ravni produkcije ključnih metabolitov PGE2 in LTC4 v celici in nato še na ravni organov, kjer preučujemo, kako je pojav bronhokonstrikcije odvisen od doze različnih NSAR. Izvedemo simulacije, v katerih napovemo časovne poteke koncentracij PGE2 in LTC4 v odvisnosti od različnih ekspresij encimov PGHS1, PGHS2 in LTC4S pri neastmatikih, aspirinsko-tolerantnih astmatikih in treh različnih populacijah aspirinsko-intolerantnih astmatikov. Simulacije izvedemo brez ali ob prisotnosti NSAR. Pokažemo, da je pojav bronhokonstrikcije odvisen od doze uporabljenega NSAR. Za aspirin, ibuprofen in celecoxib ocenimo mejne doze, pri katerih je povišano tveganje za pojav bronhokonstrikcije. Napovemo, koliko časa po zaužitju NSAR se pojavi bronhokonstrikcija in koliko časa traja. Študiramo tudi strategijo, ki bi aspirinsko-intolerantnim astmatikom omogočila varno doziranje NSAR, brez tveganja bronhokonstrikcije. Predlagamo strategijo, pri kateri bi v kombinaciji z NSAR dozirali učinkovini, ki delujeta kot inhibitorja encima 5-lipoksigenaze (5-LOX): sintetični analog PGE2 − nocloprost in učinkovina ABT-761. Rezultati kažejo, da bi spremenjeni ekspresiji PGHS1 in LTC4S utegnili biti osrednja vzroka, ki po zaužitju NSAR vodita do bronhokonstrikcije, znižana ekspresija PGHS2 pa najverjetneje vodi do drugih simptomov aspirinske intolerance. Napovedane mejne doze za aspirin in celecoxib so primerljive z eksperimentalno določenimi, o katerih poročajo v literaturi, za ibuprofen pa so nekoliko nižje. Z modelom napovedana časa od zaužitja NSAR do pojava bronhokonstrikcije in časovni interval trajanja bronhokonstrikcije sta enakega velikostnega reda, kot poročajo v literaturi. Podrobna analiza strategije doziranja NSAR z inhibitorjema 5-LOX kaže, da je nocloprost v kombinaciji z aspirinom potrebno dozirati le enkrat, v kombinaciji z ibuprofenom pa večkrat zaporedoma v različnih dozah, pri čemer so čas doziranja, doza in število doz nocloprosta odvisni od doze ibuprofena. Strategija se bistveno poenostavi, kadar namesto nocloprosta uporabimo ABT-761, ki je močan inhibitor 5-LOX s počasno fazo eliminacije iz krvne plazme.
Keywords:matematični model, aspirinska intoleranca, nesteroidni antirevmatik, arahidonska kislina, levkotrieni, prostaglandini.
Place of publishing:[Maribor
Publisher:A. Dobovišek]
Year of publishing:2012
PID:20.500.12556/DKUM-36819 New window
UDC:53
COBISS.SI-ID:262555136 New window
NUK URN:URN:SI:UM:DK:J9VULXZO
Publication date in DKUM:20.07.2012
Views:3465
Downloads:330
Metadata:XML DC-XML DC-RDF
Categories:FNM
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share



Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Secondary language

Language:English
Title:Mathematical modelling of the impact of non-steroidal anti-inflammatory drugs on aspirin intolerance in asthma
Abstract:In around 10-20 % of asthmatic patients ingestion of aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) induces bronchoconstriction, inflammation of upper airways and skin rash. This phenomenon is called aspirin intolerance. Clinical data show that altered expressions of enzymes prostaglandin H synthases 1 and 2 (PGHS1 and PGHS2) and leukotriene C4 synthase (LTC4S) in arachidonic acid (AA) metabolism could be of central importance for occurrence of aspirin intolerance. The main role is attributed to AA metabolites: inflammatory mediator leukotriene C4 (LTC4) and anti-inflammatory prostaglandin E2 (PGE2). NSAIDs inhibit the enzymes PGHS1 and PGHS2 thus increase LTC4 production and decrease PGE2 production. In this work, a mathematical model is elaborated that enables the study of the impact of different NSAIDs on the occurrence of aspirin intolerance. Mathematical model of lipoxygenase and cyclooxygenase pathway in AA metabolism is developed in which inhibitory effect of NSAID on the enzymes PGHS1 and PGHS2 is taken into account. The time course of NSAID plasma concentration is described by the standard pharmacokinetic model with absorption and elimination phases. The ratio between PGE2 and LTC4 concentrations is used as the central criterion in predictions of bronchoconstriction. The risk of bronchoconstriction is increased when the ratio between PGE2 and LTC4 concentrations is lower than 1. The occurrence of aspirin intolerance is studied on three different levels: on the level of enzymes PGHS1, PGHS2 and LTC4S expressions, on the level of PGE2 and LTC4 production in the cell and on the tissue or organ level, where the occurrence of bronchoconstriction is studied in dependence on different NSAIDs and their doses. We show that the risk of bronchoconstriction depends on the type of NSAID as well as on its dose. The limiting doses of aspirin, ibuprofen and celecoxib that may induce bronchoconstriction are calculated for different populations of aspirin-intolerant asthmatics. Further, we theoretically estimate the time between NSAID dosing and bronchoconstriction as well as duration of bronchoconstriction. We propose the strategy, which could enable safe managing of NSAIDs to aspirin-intolerant patients. The strategy is proposed in which different 5-LOX inhibitors, such as synthetic PGE2 analogue – nocloprost or ABT-761, are used in combination with NSAIDs in order to avoid bronchoconstriction. Our results identify altered expression of PGHS1 and LTC4S as the key elements of aspirin intolerance that lead to bronchoconstriction. Decreased expression of PGHS2 may lead to other symptoms of aspirin intolerance. Predicted limiting doses for aspirin and celecoxib are in the same range as measured threshold doses reported in literature. For ibuprofen, limiting doses are lower than measured threshold doses. Theoretically estimated time between NSAID dosing and bronchoconstriction, as well as the estimated duration of bronchoconstriction for different populations of aspirin-intolerant patients, are in the same order of magnitude as those observed in clinical studies. When nocloprost is used in combination with aspirin only one dose of nocloprost is needed to avoid bronconstriction. In case of ibuprofen, several consecutive doses of nocloprost should be applied. This strategy is remarkably simplified when instead of nocloprost, ABT-761 is used in combination with NSAID.
Keywords:mathematical model, aspirin – intolerance, non steroidal anti-inflammatory drug, arachidonic acid, leukotrienes, prostagladins.


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica